Pluristyx, panCELLa, and Implant Therapeutics Announce a Strategic Alliance to Manufacture and Distribute Genetically Modified, Clinical-grade Human-induced Pluripotent Stem Cells

On January 20, 2022 -Pluristyx, Inc., an advanced therapy tools and services biotechnology company, panCELLa, a privately held biotechnology company, and Implant Therapeutics, a developer of genetically engineered stem cells, reported that they have entered into a manufacturing and distribution strategic alliance that offers cell therapy companies streamlined access to the next generation of safe, universal, cost-effective, "off-the-shelf" induced pluripotent stem cells (iPSCs) (Press release, Pluristyx, 20 20, 2022, View Source [SID1234605668]). The agreement will enable commercial access to iPSCs containing panCELLa’s FailSafe and Implant’s hypoimmunogenic technology derived from fully consented and regulatory appropriate donors. Both research and clinical grade panCELLa-owned iPSC lines will be manufactured and distributed by Pluristyx, who will also make custom iPSC lines incorporating panCELLa and Implant technology to meet unique customer needs.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We evaluated many manufacturing partners and concluded that Pluristyx’s proprietary platform and mRNA reprogramming technologies provided the ideal complement to our platform technologies. We think this combination of complementary skills will enable wide dissemination of our technology."

Tweet this
Dr. Mahendra Rao, Chief Executive Officer of Implant, commented, "We evaluated many manufacturing partners and concluded that Pluristyx’s proprietary platform and mRNA reprogramming technologies provided the ideal complement to our platform technologies. We think this combination of complementary skills will enable wide dissemination of our technology."

"Pluristyx is excited to be working with panCELLa and Implant to commercialize their unique gene-edited platforms and iPSC lines. The combination of Pluristyx’s iPSC manufacturing and reprogramming technologies with panCELLa and Implant’s Stealth and FailSafe platforms will provide immediate access to a unique and ideal raw material for making the next generation of cell therapies," said Dr. Benjamin Fryer, Chief Executive Officer of Pluristyx.